Research
Hormonal
There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.
Practitioners should consider integrating pharmacotherapy with lifestyle changes and surgical options for comprehensive obesity management.
StrongSupportsmedium confidence
There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.
Why this rating
The claim is supported by recent studies and evolving treatment paradigms.
Source
Updates in pharmacotherapy of obesity
Amie Ogunsakin et al. · Journal of the National Medical Association · 2024
DOI 10.1016/j.jnma.2024.09.004
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →